Uwe Schuehly1, Surya Ayalasomayajula2, Jeppe Buchbjerg1, Parasar Pal3, Georg Golor4, Margaret F Prescott5, Gangadhar Sunkara2, Markus Hinder1, Thomas H Langenickel6. 1. Translational Medicine, Novartis Institutes for Biomedical Research, Basel, Switzerland. 2. Translational Medicine, Novartis Institutes for Biomedical Research, East Hanover, NJ, USA. 3. Biostatistical Sciences, Novartis Healthcare Pvt. Ltd., Hyderabad, India. 4. PARAXEL GmbH, Berlin, Germany. 5. Novartis Pharma AG, East Hannover, NJ, USA. 6. Translational Medicine, Novartis Institutes for Biomedical Research, Basel, Switzerland. thomas.langenickel@novartis.com.
Abstract
PURPOSE:Sacubitril/valsartan (LCZ696) and nitroglycerin share the second messenger cGMP and lower blood pressure. Given the potential for co-administration of both drugs in patients with heart failure, this study was designed to investigate the potential for a pharmacodynamic drug interaction affecting blood pressure. METHODS: In this double-blind, placebo-controlled, randomised, crossover study, 40 healthy subjects receivedsacubitril/valsartan 200 mg bid (97/103 mg bid) or placebo for 5 days. Two hours after the morning dose of sacubitril/valsartan or placebo on day 5, subjects received intravenous nitroglycerin infusion at increasing doses up to 40 μg/min or placebo. Serial measurements of blood pressure (BP), heart rate, biomarkers and sacubitril/valsartan pharmacokinetics were conducted. RESULTS: Administration of nitroglycerin alone led to a dose- and time-dependent decrease in supine systolic BP (SBP) and diastolic BP (DBP) which was similar when nitroglycerin was co-administered with sacubitril/valsartan. At the highest dose of nitroglycerin, the mean (95% CI) decrease from baseline of SBP/DBP was 19.54 (- 21.99, - 17.09)/12.38 (- 13.85, - 10.92) mmHg for nitroglycerin alone compared to 22.63 (- 25.06, - 20.21)/12.94 (- 14.38, - 11.49) mmHg when co-administered with sacubitril/valsartan. Co-administration of sacubitril/valsartan and nitroglycerin did not result in further plasma cGMP increase compared to sacubitril/valsartan alone. The co-administration of nitroglycerin and sacubitril/valsartan was safe and well tolerated and did not impact the pharmacokinetics of sacubitril/valsartan. CONCLUSIONS: The results from this study demonstrate no pharmacodynamic drug interaction between nitroglycerin and sacubitril/valsartan in healthy subjects, suggesting that no change of dose selection and escalation recommendations or clinical monitoring during nitroglycerin administration is required.
RCT Entities:
PURPOSE:Sacubitril/valsartan (LCZ696) and nitroglycerin share the second messenger cGMP and lower blood pressure. Given the potential for co-administration of both drugs in patients with heart failure, this study was designed to investigate the potential for a pharmacodynamic drug interaction affecting blood pressure. METHODS: In this double-blind, placebo-controlled, randomised, crossover study, 40 healthy subjects received sacubitril/valsartan 200 mg bid (97/103 mg bid) or placebo for 5 days. Two hours after the morning dose of sacubitril/valsartan or placebo on day 5, subjects received intravenous nitroglycerin infusion at increasing doses up to 40 μg/min or placebo. Serial measurements of blood pressure (BP), heart rate, biomarkers and sacubitril/valsartan pharmacokinetics were conducted. RESULTS: Administration of nitroglycerin alone led to a dose- and time-dependent decrease in supine systolic BP (SBP) and diastolic BP (DBP) which was similar when nitroglycerin was co-administered with sacubitril/valsartan. At the highest dose of nitroglycerin, the mean (95% CI) decrease from baseline of SBP/DBP was 19.54 (- 21.99, - 17.09)/12.38 (- 13.85, - 10.92) mmHg for nitroglycerin alone compared to 22.63 (- 25.06, - 20.21)/12.94 (- 14.38, - 11.49) mmHg when co-administered with sacubitril/valsartan. Co-administration of sacubitril/valsartan and nitroglycerin did not result in further plasma cGMP increase compared to sacubitril/valsartan alone. The co-administration of nitroglycerin and sacubitril/valsartan was safe and well tolerated and did not impact the pharmacokinetics of sacubitril/valsartan. CONCLUSIONS: The results from this study demonstrate no pharmacodynamic drug interaction between nitroglycerin and sacubitril/valsartan in healthy subjects, suggesting that no change of dose selection and escalation recommendations or clinical monitoring during nitroglycerin administration is required.
Authors: Clive Rosendorff; Henry R Black; Christopher P Cannon; Bernard J Gersh; Joel Gore; Joseph L Izzo; Norman M Kaplan; Christopher M O'Connor; Patrick T O'Gara; Suzanne Oparil Journal: Circulation Date: 2007-05-14 Impact factor: 29.690
Authors: F J Rivero-Vilches; S de Frutos; M Saura; D Rodriguez-Puyol; M Rodriguez-Puyol Journal: Am J Physiol Cell Physiol Date: 2003-06-18 Impact factor: 4.249
Authors: Dario A Vitturi; Charles Maynard; Michele Olsufka; Adam C Straub; Nick Krehel; Peter J Kudenchuk; Graham Nichol; Michael Sayre; Francis Kim; Cameron Dezfulian Journal: Redox Biol Date: 2020-02-14 Impact factor: 10.787